Navigation Links
Micromet to Present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on March 4, 2008
Date:2/29/2008

BETHESDA, Md., Feb. 29 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that Dr. Christian Itin, President and Chief Executive Officer of Micromet, will present at the Susquehanna Financial Group's SIGnificant Investment Options Conference on Tuesday, March 4, 2008, at 10:30 am ET at the W Hotel in New York.

Dr. Itin's presentation will be available on Micromet's website at http://www.micromet-inc.com following the event.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are in clinical development. MT103 (MEDI-538), the most advanced antibody in Micromet's product pipeline developed using the BiTE(R) antibody technology platform, is being developed in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia, and in a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. BiTE antibodies represent a new class of antibodies that activate a patient's own cytotoxic T cells to eliminate cancer cells. Micromet is developing MT103 in collaboration with MedImmune, Inc., a subsidiary of AstraZeneca plc. The second clinical stage antibody is adecatumumab (MT201), a human monoclonal antibody targeting EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of patients with metastatic breast cancer. The third clinical stage antibody is MT293 (TRC093), a first-in-class humanized monoclonal antibody that inhibits angiogenesis and tumor cell growth by binding cleaved collagen. MT293 is licensed to TRACON Pharmaceuticals, Inc. and is being developed in a phase 1 clinical trial for the treatment of patients with cancer and age-related macular degeneration. In addition, Micromet has established a collaboration with Nycomed for the development and commercialization of MT203, Micromet's human antibody neutralizing the activity of GM-CSF, which has potential applications in the treatment of inflammatory diseases, such as rheumatoid arthritis, as well as autoimmune diseases.


'/>"/>
SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Micromet to Present at Two Upcoming Investor Conferences
2. Micromet to Present at the 2007 RBC Capital Markets Healthcare Conference on December 12, 2007
3. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
4. Micromet to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference on November 7, 2007
5. Micromet is Presenting Four Posters on BiTE(R) Antibodies at the International AACR-NCI-EORTC Conference
6. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
7. Micromet to Present at the Sachs Associates 7th Annual Biotech in Europe Investor Forum
8. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
9. NPS Pharmaceuticals to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
10. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
11. Kosan Biosciences to Present at the Susquehanna Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/17/2019)... ... July 15, 2019 , ... CRISPR is often thought of as “molecular ... be removed, replaced, or edited, but Yiping Qi, assistant professor in Plant Science & ... in his latest publication in Nature Plants. In this comprehensive review, Qi and coauthors ...
(Date:7/17/2019)... ... July 16, 2019 , ... Quidel is the ... Kalorama Information. Abbott, Roche and Siemens Healthineers and Response Biomedical also are among ... Worldwide Market for Point-of-Care (POC) Diagnostics . , Quidel is a market leader ...
(Date:7/9/2019)... ... July 08, 2019 , ... Today, at the ... National Corn Growers Association (NCGA) announced the winners of the Consider Corn ... product or process using field corn to produce biobased materials. , “Corn is a ...
(Date:7/2/2019)... Calif. (PRWEB) , ... July 02, 2019 , ... Leading ... documentary entitled Animal Pharm: Where Beasts Meet Biotech. The film focuses on regenerative ... wild animals. Animal Pharm was recently included in the Brentwood and ...
Breaking Biology Technology:
(Date:8/4/2019)... , ... August 02, 2019 , ... Stay on top ... medical device and food industries. Access to all webinars is free, so be sure ... in your field! , Visit http://www.xtalks.com to see our upcoming webinars: , ...
(Date:8/1/2019)... ... July 30, 2019 , ... Keck ... B. and Joy Rathmann Professor in Bioprocessing and Director of the Amgen Bioprocessing ... the life sciences industry and possesses more than 25 years of global experience ...
(Date:7/26/2019)... LOS ANGELES (PRWEB) , ... July 26, 2019 ... ... pleased to announce an exclusive interview with Helius Medical Technologies CEO Phil Deschamps ... or trauma. , Helius Medical Technologies is a neurotech company in ...
Breaking Biology News(10 mins):